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Walker–Warburg syndrome (WWS) is an autosomal recessive disorder characterized by congenital muscular dystrophy, structural eye
abnormalities and severe brain malformations. We performed an immunohistochemical and electron microscopy study of a muscle biopsy
from a patient affected by WWS carrying a homozygous frameshift mutation in O-mannosyltransferase 1 gene (POMT1). a-Dystroglycan
glycosylated epitope was not detected in muscle fibers and intramuscular peripheral nerves. Laminin a2 chain and perlecan were reduced in
muscle fibers and well preserved in intramuscular peripheral nerves. The basal lamina in several muscle fibers showed discontinuities and
detachment from the plasmalemma. Most nuclei, including myonuclei and satellite cell nuclei, showed detachment or complete absence of
peripheral heterochromatin from the nuclear envelope. Apoptotic changes were detected in 3% of muscle fibers. The particular combination
of basal lamina and nuclear changes may suggest that a complex pathogenetic mechanism, affecting several subcellular compartments,
underlies the degenerative process in WWS muscle.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Walker–Warburg syndrome; a-Dystroglycan; Glycosylation; Basal lamina; Chromatin
1. Introduction fukutin remains unclear, but sequence analysis indicates thatWalker–Warburg syndrome (WWS) is an autosomal
recessive disorder characterized by congenital muscular
dystrophy, structural eye abnormalities and severe brain
malformations, including the cobblestone complex, caused
by altered neuronal migration (OMIM#236670). WWS
shares clinical features with two other genetically distinct
disorders: Fukuyama congenital muscular dystrophy
(FCMD) [OMIM#252800] and muscle-eye-brain disease
(MEB) [OMIM#253280]. WWS is more severe than FCMD
and MEB and the condition is usually lethal in the first year
of life. FCMD and MEB are both caused by mutations in
genes which encode enzymes involved in protein glycosy-
lation, Fukutin and POMGnT1, respectively. The function of0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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and glycolipids [1]. The POMGnT1 product participates in
the synthesis of O-mannosyl glycans which are widely
expressed in muscle and brain, suggesting that interference
of O-mannosyl glycosylation is a new pathomechanism for
muscular dystrophy as well as neuronal migration disorders
[2].
Recently, sequencing of O-mannosyltransferase 1 gene
(POMT1) revealed mutations in 6 out of 30 patients affected
by WWS. However, WWS shows genetic heterogeneity, so
other enzymes involved in protein O-mannosylation may be
involved in the syndrome [3].
The O-mannosyltransferase 1 is an integral protein of the
endoplasmic reticulum, which catalyzes the transfer of
mannosyl residues to serin or threonin of nascent proteins.
O-Mannosyltransferase 1 is highly expressed in fetal brain,
testis and skeletal muscle [4], tissues affected in WWS.ed.
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targets of O-mannosyltransferase 1, since a severe defi-
ciency of protein has been demonstrated in muscle tissue
from patients carrying mutations in POMT1 [3]. a-Dystro-
glycan is a crucial component of the dystrophin–glycopro-
tein complex, a group of associated proteins that play a
critical role in a variety of muscular dystrophies [5]. a-
Dystroglycan also interacts with a variety of extracellular
matrix proteins, such as perlecan and laminin a2 chain [6].
a-Dystroglycan, laminins and integrins are key structural
components of the basal lamina of muscle fibers [7]. The
integrin a7h1 represents the most prominent laminin-bind-
ing protein in mature muscle and its regulation appears to be
important for normal muscle function. In fact, mutations in
a7 integrin lead to a mild form of myopathy [8].
a-Dystroglycan is highly glycosylated and its apparent
molecular weight varies in tissues and during development
and innervation [9]. Glycosylation is important for a-dys-
troglycan binding with major extracellular matrix ligands, as
demonstrated by in vitro blocking studies [10]. Hypoglyco-
sylation and reduced expression of a-dystroglycan have
been observed in muscle biopsies from patients affected
by congenital muscular dystrophies caused by glycosylation
defects, such as Congenital Muscular Dystrophy 1C
(MDC1C) [11] and its milder allelic variant Limb-Girdle-
Muscular-Dystrophy 2I (LGMD2I) [12], as well as in
muscle from MEB [13] and FCMD patients [14], and
LARGEmyd mice [15]. Overlay assay studies demonstrated
the loss of laminin binding to a-dystroglycan in LARGEmyd
mice [15], FCMD and MEB muscle [16], suggesting that
cell–extracellular matrix interaction impairment could con-
tribute to pathogenesis of muscular dystrophies caused by
glycosylation defects. This hypothesis is supported by
studies that report sarcolemma alterations in FCMD and
LARGEmyd mice [15,17].
In a muscle biopsy from a WWS patient carrying
homozygous mutation in POMT1, we found a severe
deficiency of a-dystroglycan glyco-epitope in muscle and
intramuscular peripheral nerve, while laminin a2 chain,
perlecan and basal lamina organization were selectively
altered in muscle fibers. An altered chromatin organization
was also detected in most myonuclei. The association of
basal lamina and nuclear changes we found in WWS muscle
has never been documented in other forms of muscular
dystrophies and suggests that impaired glycosylation caused
by mutated POMT1 may affect not only the extracellular
compartment organization but also intracellular compo-
nents.2. Materials and methods
The patient was a gypsy boy who exhibited severe
hypotonia, ocular malformation and hydrochephalus at
birth. MRI showed huge ventricular dilatation, lissence-
phaly type II, vermis hypoplasia and agenesis of corpuscallosum. Ocular examination showed buphthalmus, retinal
dysplasia and lens opacity. CK was 16973 (normal < 195)
on day 2, and 3562 at 1 month of age [18]. He was found
to carry a homozygous frameshift mutation 2110InsG in
exon 20 in POMT1 gene. This mutation causes a replace-
ment of the 44 highly conserved C-terminal amino acids
by 26 new ones after Val703 (family 4 in Ref. [3]). The
course was marked by the absence of psychomotor devel-
opment and occurrence of infantile spasms. He died at the
age of 2 1 2= years. A third-degree cousin of the proband
had the same signs at birth but was not examined and died
at the age of 40 days. For immunohistochemical analysis,
muscle biopsy of the proband affected by WWS and of
two age-matched controls were snap frozen in liquid
nitrogen-cooled isopentane and stored in liquid nitrogen.
Seven-micrometer-thick sections were air-dried for 2 h at
room temperature, fixed in 2% paraformaldehyde in PBS
for 10 min at 4 jC, washed with PBS and incubated with
anti-a-dystroglycan VIA4-1 antibody (Upstate Biotechnol-
ogy), raised against the glycosylated protein for 1 h at
room temperature, diluted 1:100. Anti-nidogen (Calbio-
chem), perlecan (Chemicon), collagen type VI (Chemicon)
and collagen type IV (Chemicon), h-bystroglycan (Novo-
castra), dystrophin (Novocastra) and caveolin 3 (BD-
Transduction) were used on unfixed frozen sections
according to the manufacturer’s instructions. Aceton-fixed
sections were used for detection of integrin a7B using a
rabbit polyclonal antibody (kind gift of E. Engvall) diluted
1:100.
All samples were incubated with anti-mouse, anti-sheep
or anti-rabbit FITC- or TRITC-conjugated secondary anti-
bodies (DAKO), washed several times and observed with a
Nikon E 600 fluorescence microscope. To label apoptotic
nuclei, the fragmented DNA was visualized by the method
of terminal transferase-mediated dUTP nick end-labeling
(TUNEL) using the Apoptosis Detection System fluores-
cence kit (Promega, WI, USA) according to the manufac-
turer’s instructions. The nuclei were counterstained with
DAPI. In order to evaluate the morphological aspect of
TUNEL positive fibers, the same areas were analyzed after
hematoxilin eosin staining.
Some blocks of tissue were stretched on dental wax and
fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer
for 3 h and with 1% osmium tetroxide in Veronal buffer for
1 h, dehydrated with ethanol, and embedded in Epon E812.
Transverse ultrathin sections were obtained from several
blocks, stained with lead citrate and uranyl acetate and
observed by a Philips EM 400 transmission electron micro-
scope, operated at 100 kV.
Sections obtained from seven tissue blocks were ob-
served at the same magnification (30,000 ). About 200
nuclei were observed for monitoring nuclear alterations;
apoptosis incidence was confirmed by examining further
400 nuclei.
The institutional ethics committee of each center ap-
proved the protocol.
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The muscle biopsy from the WWS patient showed
dystrophic changes consisting of increased fiber size varia-
bility, connective tissue proliferation, internal nuclei,
necrosis and regeneration. The immunohistochemical anal-
ysis of the h-dystroglycan, caveolin 3 and dystrophin (not
shown) revealed a normal labelling. The a-dystroglycan
glyco-epitope was almost undetectable in muscle fibers and
intramuscular peripheral nerves (Fig. 1A). Laminin a2 chain
(Fig. 1B) and perlecan (Fig. 1A) were severely reduced in
most muscle fibers but normally present in intramuscular
peripheral nerves. The expression of integrin a7B was
severely reduced in muscle fibers when compared with
age-matched muscle controls (Fig. 1B). Other extracellu-
lar-matrix proteins such as collagen type IV, collagen type
VI and nidogen were normal (not shown).
By electron microscope examination, we found altera-
tions in non-necrotic WWS muscle fibers in two distinct
subcellular compartments: the basal lamina and the nucleus.Fig. 1. (A) The double-labeling of anti-perlecan and a-dystroglycan (a-DG)
VIA4-1 antibodies in normal control and WWS muscle biopsy reveals a
selective deficiency of perlecan in some muscle fibers (asterisks) while
intramuscular peripheral nerves (arrows) and vessels show a normal
labeling. The a-dystroglycan appears absent both in muscle and intra-
muscular peripheral nerves. (B) The immunofluorescence analysis of
laminin a2 chain shows a selective deficiency of labeling in muscle fibers
of WWS patient while the intramusclular peripheral nerves (arrows) show a
pattern comparable with control. The integrin a7B reveals a selective
deficiency of protein in WWS muscle fibers. Bar 30 Am.
Fig. 2. Electron microscope analysis of skeletal muscle fibers from control
(A) and WWS patient (B–F). In control muscle (A) the basal lamina
appears as a continuous layer that surrounds the muscle fiber tightly
associated to the plasmalemma. WWS muscle fibers show interruption of
basal lamina (B, D) and detachments from the plasmalemma (B). Basal
lamina alterations correspond in some cases to plasmalemma disruption
(asterisk, B). A myelinic fiber of an intramuscular peripheral nerve shows
normal basament membrane (E). Peripheral heterochromatin of a
myonucleus (C) and a satellite cell (F) appears completely detached from
the nuclear lamina. The nuclear cisterna is dilated in C and F. Irregular
shape and nuclear membrane projections of nuclear envelope are shown in
the inset in C. The cytoplasm of both myofiber and satellite cell appears
normal. Bar 250 nm.The basal lamina of muscle fibers revealed several disconti-
nuities and detachments from the plasmalemma (Fig. 2). In
contrast, basal lamina of the intramuscular peripheral nerves
appeared continuous and attached to the membrane of
Schwann cells and the organization of myelin sheets was
normal (Fig. 2).
Eighty percent of 200 nuclei from several blocks of
tissue, including both myofiber and satellite cell nuclei,
showed complete detachment of peripheral heterochromatin
from the nuclear envelope and hypercondensed heterochro-
matin clumps. The nuclear envelope showed a dilated
cisterna and a marked loss of nuclear pores, while the
nuclear lamina was preserved and showed a regular thick-
ness. Some nuclei showed an irregular shape characterized
by several papillary projections of nuclear envelope often
lacking heterochromatin (Fig. 2).
Two percent of 600 muscle fiber nuclei examined
showed the characteristic changes of apoptosis, consisting
of highly condensed, marginated chromatin at the inner
Fig. 3. (A) Apoptotic myonucleus in WWS muscle longitudinal section. On
the left a nucleus stained for DNA fragmentation by the TUNEL method.
DAPI staining allows detection of nuclei present in the section (right); (B)
electron microscope study of muscle biopsy from WWS patient showing
characteristic apoptotic changes, consisting of highly condensed chromatin,
marginated along the inner surface of the nuclear envelope, associated with
dilated endoplasmic reticulum and condensed mitochondria (left). The
nucleus of a satellite cell displayed a half-moon-like condensed chromatin
(right). Bar 250 nm.
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endoplasmic reticulum and condensed mitochondria (Fig.
3). For quantitative analysis, only fibers with both hetero-
chromatin and cytoplasmic apoptotic changes were consid-
ered. TUNEL on muscle sections from the patient showed a
positive staining in 3% of nuclei of muscle fibers and 1% of
the interstitial cells (Fig. 3). TUNEL positive nuclei were
detected in non-necrotic muscle cells as revealed by hem-
atoxilin eosin staining of the same TUNEL treated sections
(not shown).4. Discussion
In the present study we describe extracellular matrix and
nuclear alterations in the muscle biopsy from a patient withWWS caused by mutations in POMT1. These consisted of
altered basal lamina composition and organization, chroma-
tin and nuclear envelope abnormalities, and apoptosis.
a-Dystroglycan glyco-epitope was almost undetectable
in the muscle and intramuscular peripheral nerves of the
patient, suggesting that a-dystroglycan, an O-mannosylated
protein, could be a target of O-mannosyltransferase 1. Other
glycosyltransferases have been shown to be implicated in a-
dystroglycan posttranslational modification and their muta-
tion causes WWS-overlapping phenotypes, showing that a-
dystroglycan plays a key role in pathogenesis of muscular
dystrophies with brain abnormalities [19]. Hypoglycosy-
lated dystroglycan from FCMD, MEB and LARGEmyd mice
failed to bind extracellular ligands, suggesting that abnormal
dystroglycan–ligand interactions underlie the pathogenetic
mechanism of these disorders [16]. The glycosylated moiety
of a-dystroglycan is crucial for binding with extracellular
ligands, such as laminins and perlecan, which connect the
sarcolemma with the extracellular matrix [6]. Thus, a-
dystroglycan alterations may affect extracellular matrix
integrity of WWS patients with mutations in the POMT1
gene. In order to verify this hypothesis, we studied the
structural organization of the basal lamina and the expres-
sion of extracellular a-dystroglycan-associated proteins, as
laminin a2 chain and perlecan, and we found a selective
involvement of muscle fibers. In fact, laminin a2 chain and
perlecan were reduced in muscle fibers but not in intra-
muscular peripheral nerves. It is noteworthy that a different
glycosylation pattern of a-dystroglycan is present in muscle
(156-kDa protein) in comparison with nerves (120-kDa
protein) [20].
We found basal lamina alterations consisting of detach-
ment from the plasma membrane, focal loss and interrup-
tions. Interestingly, these alterations were detected in
myofibers which did not show necrotic changes, suggesting
that sarcolemmal alterations represent an early event and the
destabilization of the plasmalemma binding to the extrac-
ellular matrix may play a primary role in degeneration of
WWS muscle fibers. Basal lamina alterations have been
described in several forms of muscular dystrophies with
primary and secondary defects of structural components
involved in cytoskeleton–extracellular matrix interaction.
In Duchenne muscular dystrophy, the absence of dystrophin
leads to secondary deficiency of sarcoglycans and dystro-
glycans, which is reflected by reduplication, focal loss and
detachment of basal lamina from the membrane of muscle
fibers [21]. A recent study demonstrated detachment and
duplication of basal lamina in Largemyd mouse with normal
dystrophin and secondary involvement of a-dystroglycan
caused by glycosyltransferase defect [15]. Derangement and
interruptions of basal lamina in non-necrotic muscle fibers
have been found in one case of WWS [22] and in other
muscular dystrophies due to primary laminin a2 chain
deficiency [23,24], as well as in FCMD [17] with secondary
involvement of a-dystroglycan and laminin a2 chain. In our
WWS patient we previously found deficiency of a-sarco-
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muscle fibers, so that the basal lamina derangement we
report here can be ascribed to the deficiency of these
sarcolemmal components.
It is interesting to note that basal lamina appears normal
in chimeric dystroglycan deficient mice, lacking a and h-
dystroglycan, and mdx mice, both of which show secon-
dary deficiency of dystroglycan. This may result from
compensation by other extracellular matrix ligands, such
as integrin a7B which has been reported to be upregulated
in mdx mice and chimeric dystroglycan mice [25]. On the
other hand, dy/dy mice [26] and laminin a2 chain-deficient
muscular dystrophy show decreased levels of a7B integrin
and basal lamina appears damaged. Interestingly, we found
a decreased expression of integrin a7B in WWS muscle
fibers. This alteration, in addition to a-dystroglycan defi-
ciency, suggests that the major mechanisms of attachment
of the cytoskeleton to the extracellular matrix are impaired
in WWS muscle fibers and can underlie the structural
defect.
Altered interaction of muscle cells with the extracellular
matrix can induce apoptosis [27–29]. In order to investigate
if apoptosis may contribute to cell death in tissues affected
by POMT1 mutations, we performed the TUNEL assay to
detect DNA fragmentation, and electron microscopy to
detect the characteristic morphological changes. Three per-
cent of muscle nuclei appeared positive to TUNEL and 2%
showed the typical morphological alterations under the
electron microscope, suggesting that programmed cell death
contributes to myofiber degeneration in WWS. The involve-
ment of satellite cells indicates that regenerative/repair
mechanisms might be also altered.
Electron microscope examination also revealed striking
alterations of heterochromatin organization in 80% of
nuclei. These nuclear defects were unlikely to be related
to apoptosis; in fact, they were far more frequent than
apoptotic changes (80% versus 3%). The high percentage
of nuclei showing these alterations in fibers lacking evident
signs of degenerative processes suggests that nuclear
involvement is upstream of other pathogenetic events.
Although evidence of glycosyl transferase [30] and O-
mannosyl transferase activity [31] have been described in
the nucleus and O-linked N-acetylglucosamine (O-GlcNAc)
glycosylation has also been reported as a major modification
of chromatin proteins, transcription factors and nucleoporins
[32,33], nuclear alterations have never been reported in
muscular dystrophies linked to glycosylation defects. Sub-
strates of glycosylation enzymes play a role in regulating
gene expression [34]. In this respect, we cannot rule out the
possibility that altered function of POMT1 may elicit down-
stream effects by altering signal transduction mechanisms.
Interestingly, nuclear alterations consisting of vacuoles
throughout the nucleus have been recently described in
dystroglycan-deficient chimeric mice [25]. Thus, the chro-
matin defects here observed in WWS muscle could be also
related to dystroglycan deficiency. It is also worthy to notethat a-dystroglycan is involved in the activation of signaling
pathways [6] which might trigger intranuclear events.
This association of basal lamina and nuclear changes has
never been described in other forms of muscular dystrophies
and suggests that impaired glycosylation caused by POMT1
mutations induces degenerative changes, probably through a
complex mechanism affecting cellular and extracellular
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